Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients With Moderate to Severe Plaque Psoriasis: Post-Hoc Results from Five Phase 3 3b Trials. J of Skin 2024, 8 (1), s303. https://doi.org/10.25251/skin.8.supp.303.